Budweiser Brewing Company APAC Limited (BDWBY) Q1 2026 Earnings Call Transcript
Budweiser Brewing Company APAC Limited (BDWBY) Q1 2026 Earnings Call Transcript
seekingalpha.com
SUPN(SUPN)
SUPN
Signal
Leaning Bullish2↑1↓
PRICE
Prev Close
47.85
Open
47.53
Day Range47.34 – 49.01
47.34
49.01
52W Range29.16 – 59.68
29.16
59.68
64% of range
VOLUME & SIZE
Avg Volume
696.0K
FUNDAMENTALS
P/E Ratio
-70.5x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Beta
0.70
Low vol
Performance
1D
+1.63%5D
+0.43%1M
-3.78%3M
-0.92%6M↓
-14.68%YTD
-2.15%1Y↑
+50.14%Best: 1Y (+50.14%)Worst: 6M (-14.68%)
Quick Read
Trend—Insufficient MA data
Momentum
BULLISH
revenue +9% YoY · 86% gross marginValuation
FAIR
P/E not availableHealth
STRONG
CR 1.9 · FCF $0.80/shStrong Buy
Key MetricsTTM
Market Cap$2.80B
Revenue TTM$718.95M
Net Income TTM-$38.55M
Free Cash Flow$45.99M
Gross Margin85.5%
Net Margin-5.4%
Operating Margin-6.2%
Return on Equity-3.7%
Return on Assets-2.7%
Debt / Equity0.04
Current Ratio1.90
EPS TTM$-0.67
Alpha SignalsView Intelligence →
Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.
Health Radar
1 strong1 watch4 concern
32/100Liquidity
1.90Watch
Leverage
0.04Strong
Coverage
0.0xConcern
ROE
-3.7%Concern
ROIC
-3.1%Concern
Cash
$128MConcern
ANALYST COVERAGE14 analysts
BUY
▲ +23.4%upside to target
L $55.00
Med $60.00consensus
H $65.00Stock Health
Composite Score
4 of 5 signals bullish
8/10
Technicals
●
✗RSI RangeRSI 49 — Bearish momentum
Volume
●
✓Volume FlowAccumulation — institutional buying
Fundamentals
●
✓Last EarningsBeat estimates
●
✓Analyst ConsensusBuy
●
✓LiquidityCurrent Ratio 1.90 — healthy liquidity
Upcoming Events
EEarnings ReportMay 6, 2026
Tomorrow
DEx-Dividend DateAug 3, 2026
In 90 days
PDividend PaymentSep 1, 2026
In 119 days
FinancialsFull statements →
Technicals
Technical SetupBEARISH
Technicals →Trend
→ PullbackGolden Cross · 50D leads 200D by 12.9%
-4.7% vs SMA 50 · +7.6% vs SMA 200
Momentum
RSI48.6Neutral territory
MACD-0.76Below zero — bearish pulse · compressing
Market Position
Price Levels
52W High
$59.68+22.7%
EMA 50
$50.84+4.5%
Current
$48.63
EMA 200
$44.60-8.3%
52W Low
$29.16-40.0%
52-Week RangeMid-range
$29.1664th %ile$59.68
Squeeze SetupVolume-based
Moderate Squeeze SetupAccumulation pattern present — more buying days than selling over the past 20 sessions. Volume conditions support gradual price improvement.
20-Day Money Flow
Acc days:7
Dist days:6
Edge:+1 acc
Volume Context
Avg Vol (50D)625K
Recent Vol (5D)
747K+20%
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
Earnings & Analysts
ANALYST ESTIMATES
Consensus of 4 analysts
Analyst revisions:EPS↑ Revised UpRevenue↓ Revised Down
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2025 | $702.5M $702.0M–$703.0M | — | $3.10 | — | ±1% | Moderate4 |
FY2026(current) | $862.2M $858.0M–$866.4M | ▲ +22.7% | $2.17 | ▼ -30.0% | ±11% | Moderate4 |
FY2027 | $1.0B $996.0M–$1.0B | ▲ +19.0% | $3.94 | ▲ +81.9% | ±9% | Moderate4 |
Range confidence:Tight (high)ModerateWide (low)
🔥Beat 7 consecutive quarters
Earnings HistorySUPN
Last 8Q
+71.9%avg beat
Beat 7 of 8 quartersMissed 1↑ Estimates rising-32%
Q2'24
+16%
Q3'24
+172%
Q4'24
+63%
Q1'25
+11%
Q2'25
+94%
Q3'25
+23%
Q4'25
+229%
Q1'26
Beat
Miss
Estimate
Deeper color = bigger beat/miss
Analyst Activity
All ratings →No recent activity
Piper SandlerNeutral → Overweight
Oct 9
UPGRADE
Piper SandlerOverweight → Neutral
Sep 10
DOWNGRADE
Insider Activity
SEC Filings →0 Buys/6 SellsNet Selling
Bhatt Padmanabh P.Sr. VP of IP, …
$1.4M
Mar 17
SELL
Bhatt Padmanabh P.Sr. VP of IP, …
$1.7M
Mar 16
SELL
Bhatt Padmanabh P.Sr. VP of IP, …
$339K
Mar 18
SELL
Bhatt Padmanabh P.Sr. VP of IP, …
$1.1M
Mar 17
SELL
Bhatt Padmanabh P.Sr. VP of IP, …
$802K
Mar 16
SELL
Bhatt Padmanabh P.Sr. VP of IP, …
$21K
Mar 18
SELL
Financials
INSTITUTIONAL OWNERSHIP
1
Stephens Investment Management Group LLC
1.4M▼2
Assenagon Asset Management S.A.
531K▲3
Pictet Asset Management Holding SA
451K▼4
SG Americas Securities, LLC
377K▲5
PRINCIPAL FINANCIAL GROUP INC
341K▲6
abrdn plc
276K▲7
Nuveen, LLC
216K▲8
TEACHER RETIREMENT SYSTEM OF TEXAS
130K▼News & Activity
SUPN News
20 articles · 4h ago
Intertek surges on third offer from Swedish private equity firm EQT
proactiveinvestors.co.uk
Mastercard Targets the Hidden Cost of Late B2B Payments
pymnts.com
Strauss Group Announces Timing of First Quarter 2026 Earnings Release and Webcast
prnewswire.com
ECCA and TTEC Release “Visionary Voices” Research on the Future of Contact Centre Sales in Europe
globenewswire.com
Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting
globenewswire.com
Schindler Selects Navan to Elevate Global Travel Operations
businesswire.com
Volkswagen Financial Services Poland marks three years of strong ABS performance with BearingPoint
businesswire.com
European shares slip as US-Iran tensions escalate, oil stays elevated
invezz.com
Stock Market Today: Brent Crude Steadies Near Multiyear High
wsj.com
Oil Price Forecast: Brent and WTI Eye Breakout as Fuel Shortage Risk Grows
fxempire.com
PWB: High Expectations, Compressed Forward Returns, A Fundamental Avoid At Present
seekingalpha.com
Faron Pharmaceuticals Ltd: Holding(S) In Company
accessnewswire.com
Hexagon Purus ASA: Invitation to the presentation of first quarter 2026 results
globenewswire.com
Apple's chip talks with Intel and Samsung signal a structural shift in how Big Tech thinks about supply chain risk
proactiveinvestors.co.uk
Lululemon Stock Investors Might Be Surprised to See This
fool.com
CSL: The Plasma Moat Is Being Rebuilt While The Market Prices The Noise
seekingalpha.com
The Baldwin Insurance Group, Inc. (BWIN) Q1 2026 Earnings Call Transcript
seekingalpha.com
What UniCredit's $28B Commerzbank bid mean for European banking?
invezz.com
Trump Plays Down Iran Attacks on Ships in Hormuz. Oil Prices Tell a Different Story.
barrons.com
About
pioneering new medicines in neurology and psychiatry with more than 20 years of experience, we are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (cns) disorders. in 2013 we launched oxtellar xr® and trokendi xr®, two novel neurology products for the treatment of epilepsy. we are also developing several product candidates in psychiatry to address unmet medical needs and opportunities in attention-deficit hyperactivity disorder (adhd) and its coexisting disorders, and depression. we are developing differentiated products by leveraging our proprietary and in-licensed technologies. we use such technologies to discover and develop novel uses for known drug compounds and to enhance their therapeutic benefits. our focus on known drug compounds with established mechanisms of action reduces the risks, costs, and time typically associated with pharmaceutical product development.
Industry
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
CEO
Jack Khattar
Website
Jonathan RubinSenior Vice President of Research & Development and Chief Medical Officer
Padmanabh BhattChief Scientific Officer & Senior Vice President of Intellectual Property
Jack A. KhattarFounder, President, Chief Executive Officer, Secretary & Director
Peers— Health Care(7 companies)
Screen sector →| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
SUPN◀ | $48.63 | +1.63% | $2.8B | — | +863.3% | -536.2% | 1500 |
| $68.99 | +0.00% | $13.4B | — | — | — | 1500 | |
| $91.17 | +0.00% | $12.0B | — | — | -4239.0% | 1500 | |
| $518.66 | +0.96% | $11.9B | — | — | -3008.0% | 1500 | |
| $223.70 | +8.31% | $11.4B | — | +6554.5% | -2868.8% | 1500 | |
| $76.39 | +0.00% | $10.7B | 52.9 | +2325815.3% | -19.7% | 1500 | |
| $182.03 | +0.00% | $10.6B | — | — | — | 1500 | |
| Sector avg | — | +1.56% | — | 52.9 | +777744.4% | -2134.3% | 1500 |